Gufic Biosciences Limited (GUFICBIO.BO)
INR 449.05
(0.28%)
INR 449.05
(0.28%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.06 Billion INR | 16.8% |
| 2022 | 6.9 Billion INR | -11.36% |
| 2021 | 7.79 Billion INR | 59.76% |
| 2020 | 4.87 Billion INR | 28.74% |
| 2019 | 3.78 Billion INR | 8.0% |
| 2018 | 3.5 Billion INR | 14.79% |
| 2017 | 3.05 Billion INR | 24.47% |
| 2016 | 2.45 Billion INR | 21.42% |
| 2015 | 2.02 Billion INR | 33.42% |
| 2014 | 1.51 Billion INR | 23.2% |
| 2013 | 1.23 Billion INR | 22.83% |
| 2012 | 1 Billion INR | 19.84% |
| 2011 | 835.65 Million INR | 16.93% |
| 2010 | 714.65 Million INR | 13.64% |
| 2009 | 628.86 Million INR | 21.67% |
| 2008 | 516.84 Million INR | -4.46% |
| 2007 | 540.94 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.02 Billion INR | 0.51% |
| 2023 Q3 | 2.01 Billion INR | -6.09% |
| 2023 Q4 | 2.01 Billion INR | 0.0% |
| 2023 FY | 8.06 Billion INR | 16.8% |
| 2023 Q2 | 2.14 Billion INR | 10.18% |
| 2023 Q1 | 1.95 Billion INR | 12.71% |
| 2022 FY | 6.9 Billion INR | -11.36% |
| 2022 Q3 | 1.77 Billion INR | 1.51% |
| 2022 Q4 | 1.73 Billion INR | -2.5% |
| 2022 Q1 | 1.65 Billion INR | 1.9% |
| 2022 Q2 | 1.74 Billion INR | 5.78% |
| 2021 Q3 | 1.72 Billion INR | -11.37% |
| 2021 Q4 | 1.62 Billion INR | -5.74% |
| 2021 Q1 | 2.5 Billion INR | 48.55% |
| 2021 FY | 7.79 Billion INR | 59.76% |
| 2021 Q2 | 1.94 Billion INR | -22.58% |
| 2020 FY | 4.87 Billion INR | 28.74% |
| 2020 Q4 | 1.68 Billion INR | 1.35% |
| 2020 Q3 | 1.66 Billion INR | 29.7% |
| 2020 Q2 | 1.28 Billion INR | 111.22% |
| 2020 Q1 | 607.96 Million INR | -25.49% |
| 2019 Q4 | 815.9 Million INR | -16.53% |
| 2019 Q3 | 977.44 Million INR | 13.62% |
| 2019 Q2 | 860.25 Million INR | -6.89% |
| 2019 Q1 | 923.9 Million INR | 0.52% |
| 2019 FY | 3.78 Billion INR | 8.0% |
| 2018 Q3 | 876.52 Million INR | -5.16% |
| 2018 FY | 3.5 Billion INR | 14.79% |
| 2018 Q4 | 919.13 Million INR | 4.86% |
| 2018 Q2 | 924.2 Million INR | 0.95% |
| 2018 Q1 | 915.48 Million INR | 18.24% |
| 2017 Q1 | 602.68 Million INR | -3.2% |
| 2017 FY | 3.05 Billion INR | 24.47% |
| 2017 Q3 | 896.13 Million INR | 19.04% |
| 2017 Q4 | 774.24 Million INR | -13.6% |
| 2017 Q2 | 752.81 Million INR | 24.91% |
| 2016 FY | 2.45 Billion INR | 21.42% |
| 2016 Q2 | 641.92 Million INR | 16.5% |
| 2016 Q1 | 550.98 Million INR | -3.74% |
| 2016 Q4 | 622.62 Million INR | -3.96% |
| 2016 Q3 | 648.27 Million INR | 0.99% |
| 2015 Q1 | 375.92 Million INR | 5.59% |
| 2015 Q2 | 513.07 Million INR | 36.48% |
| 2015 Q3 | 560.59 Million INR | 9.26% |
| 2015 FY | 2.02 Billion INR | 33.42% |
| 2015 Q4 | 572.39 Million INR | 2.11% |
| 2014 Q3 | 342.31 Million INR | -19.72% |
| 2014 Q4 | 356.01 Million INR | 4.0% |
| 2014 Q2 | 426.38 Million INR | 9.1% |
| 2014 Q1 | 390.8 Million INR | 4.72% |
| 2014 FY | 1.51 Billion INR | 23.2% |
| 2013 Q2 | 290.14 Million INR | 14.37% |
| 2013 Q4 | 373.18 Million INR | 19.2% |
| 2013 FY | 1.23 Billion INR | 22.83% |
| 2013 Q3 | 313.08 Million INR | 7.91% |
| 2013 Q1 | 253.69 Million INR | 2.78% |
| 2012 FY | 1 Billion INR | 19.84% |
| 2012 Q1 | 271.4 Million INR | 24.5% |
| 2012 Q4 | 246.83 Million INR | 0.27% |
| 2012 Q3 | 246.17 Million INR | 3.86% |
| 2012 Q2 | 237.03 Million INR | -12.66% |
| 2011 Q3 | 219.63 Million INR | 0.0% |
| 2011 FY | 835.65 Million INR | 16.93% |
| 2011 Q4 | 217.99 Million INR | -0.75% |
| 2010 FY | 714.65 Million INR | 13.64% |
| 2009 FY | 628.86 Million INR | 21.67% |
| 2008 FY | 516.84 Million INR | -4.46% |
| 2007 FY | 540.94 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 80.833% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -91.502% |
| Sigachi Industries Limited | 3.98 Billion INR | -102.194% |
| Bal Pharma Limited | 3.39 Billion INR | -137.8% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 37.024% |
| Medico Remedies Limited | 1.44 Billion INR | -456.626% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -673.15% |
| Venus Remedies Limited | 5.91 Billion INR | -36.388% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -967.791% |
| Alpa Laboratories Limited | 1.08 Billion INR | -641.837% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 52.101% |
| Shilpa Medicare Limited | 11.51 Billion INR | 29.953% |
| Aarti Drugs Limited | 25.28 Billion INR | 68.098% |
| Lupin Limited | 200.1 Billion INR | 95.969% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 97.19% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 95.759% |
| Windlas Biotech Limited | 6.3 Billion INR | -27.848% |
| Suven Life Sciences Limited | 116.92 Million INR | -6798.765% |
| Eris Lifesciences Limited | 20.09 Billion INR | 59.85% |
| Valiant Laboratories Limited | 1.82 Billion INR | -343.084% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 76.848% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 34.862% |
| Ipca Laboratories Limited | 76.22 Billion INR | 89.417% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -4.728% |
| Achyut Healthcare Limited | 61.36 Million INR | -13044.514% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.337% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -70.392% |
| RPG Life Sciences Limited | 5.82 Billion INR | -38.59% |
| Mankind Pharma Limited | 103.34 Billion INR | 92.195% |
| Laurus Labs Limited | 50.01 Billion INR | 83.872% |
| Piramal Pharma Limited | 81.71 Billion INR | 90.128% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -211.161% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 92.394% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 86.802% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 93.171% |
| Unichem Laboratories Limited | 16.57 Billion INR | 51.33% |
| Sequent Scientific Limited | 13.69 Billion INR | 41.108% |
| Novartis India Limited | 3.35 Billion INR | -140.745% |
| Wanbury Limited | 5.75 Billion INR | -40.131% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 23.274% |
| Wockhardt Limited | 27.89 Billion INR | 71.077% |
| Themis Medicare Limited | 3.81 Billion INR | -111.301% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -286.516% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 87.965% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 64.67% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 97.11% |
| Divi's Laboratories Limited | 78.45 Billion INR | 89.717% |
| NATCO Pharma Limited | 40.02 Billion INR | 79.843% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 61.931% |
| Ind-Swift Limited | 5.02 Billion INR | -60.541% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 29.932% |
| FDC Limited | 19.42 Billion INR | 58.482% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -1499.845% |
| Granules India Limited | 45.06 Billion INR | 82.099% |
| Medicamen Biotech Limited | 1.79 Billion INR | -349.882% |
| Alkem Laboratories Limited | 126.67 Billion INR | 93.632% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 37.735% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1914.886% |
| Brooks Laboratories Limited | 794.86 Million INR | -914.851% |
| Megasoft Limited | 373.95 Million INR | -2057.131% |
| ZIM Laboratories Limited | 3.67 Billion INR | -119.546% |
| Strides Pharma Science Limited | 40.51 Billion INR | 80.088% |
| Neuland Laboratories Limited | 15.58 Billion INR | 48.244% |
| Morepen Laboratories Limited | 17.01 Billion INR | 52.602% |
| Hikal Limited | 17.84 Billion INR | 54.799% |
| Indoco Remedies Limited | 17.89 Billion INR | 54.921% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 55.568% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -422.545% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -118.849% |
| Hester Biosciences Limited | 3.04 Billion INR | -164.875% |